IE
ZVRA icon

Israel Englander’s Zevra Therapeutics ZVRA Stock Holding History

Israel Englander’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
90,461
-499,808
-85% -$5.56M ﹤0.01% 4143
2026
Q1 		$5.5M Sell
590,269
-544,089
-48% -$4.9M ﹤0.01% 2825
2025
Q4 		$10.2M Buy
1,134,358
+99,107
+10% +$937K ﹤0.01% 2246
2025
Q3 		$9.85M Buy
1,035,251
+400,431
+63% +$4.02M ﹤0.01% 2401
2025
Q2 		$5.59M Buy
634,820
+526,119
+484% +$4.27M ﹤0.01% 2867
2025
Q1 		$814K Sell
108,701
-124,431
-53% -$989K ﹤0.01% 4501
2024
Q4 		$1.94M Buy
233,132
+135,246
+138% +$1.15M ﹤0.01% 3670
2024
Q3 		$679K Buy
+97,886
New +$664K ﹤0.01% 4583
2023
Q2 		– Sell
-153,053
Closed -$842K – 6778
2023
Q1 		$842K Buy
153,053
+63,634
+71% +$337K ﹤0.01% 4251
2022
Q4 		$410K Sell
89,419
-75,884
-46% -$385K ﹤0.01% 4882
2022
Q3 		$1.03M Sell
165,303
-171,944
-51% -$974K ﹤0.01% 4318
2022
Q2 		$1.5M Buy
337,247
+16,969
+5% +$77.4K ﹤0.01% 3988
2022
Q1 		$1.61M Buy
+320,278
New +$2.04M ﹤0.01% 4075
2021
Q2 		– Sell
-212,650
Closed -$1.96M – 7206
2021
Q1 		$1.96M Buy
+212,650
New +$1.86M ﹤0.01% 3565
2018
Q3 		– Sell
-9,453
Closed -$983K – 4333
2018
Q2 		$983K Buy
9,453
+8,486
+878% +$828K ﹤0.01% 2845
2018
Q1 		$122K Buy
+967
New +$93.5K ﹤0.01% 3459
2017
Q2 		– Sell
-936
Closed -$73K – 3932
2017
Q1 		$73K Sell
936
-729
-44% -$44.3K ﹤0.01% 3358
2016
Q4 		$79K Buy
1,665
+100
+6% +$6.14K ﹤0.01% 3217
2016
Q3 		$112K Sell
1,565
-2,185
-58% -$155K ﹤0.01% 3108
2016
Q2 		$239K Buy
3,750
+2,294
+158% +$377K ﹤0.01% 2833
2016
Q1 		$338K Buy
+1,456
New +$353K ﹤0.01% 2718
2015
Q4 		– Sell
-2,029
Closed -$629K – 3819
2015
Q3 		$629K Buy
+2,029
New +$621K ﹤0.01% 2548

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Israel Englander's ZVRA Position: Q2 2026 in Review

Israel Englander reduced its Zevra Therapeutics (ZVRA) stake by 85% in Q2 2026, selling an estimated $5.56M and leaving 90,461 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4143.

Israel Englander first reported a position in ZVRA in Q3 2015 and has held it in 22 quarters since. The position peaked at $10.2M in Q4 2025. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Israel Englander held 90,461 shares of Zevra Therapeutics worth $1.3M as of Q2 2026.
  • Israel Englander sold 499,808 Zevra Therapeutics shares in Q2 2026, an estimated $5.56M.
  • Zevra Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4143 holding.
  • Israel Englander first reported a position in Zevra Therapeutics in Q3 2015 and has held it in 22 quarters since.
  • Israel Englander's Zevra Therapeutics position peaked at $10.2M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.